Freenome Colorectal Cancer Test Data Improve on Earlier Results

Freenome colorectal cancer test data improve on earlier results

The new study results could make Abbott, which has an agreement with Freenome to market the blood-based test, the dominant player in colorectal cancer screening, Evercore ISI analysts said.

Freenome Reports Clinical Validation Results for Updated Colorectal Cancer Blood Test

SimpleScreen CRC blood test met all primary and secondary endpoints in clinical validation, with improved sensitivity for precancerous lesions and colorectal cancer. Freenome announced results from a clinical validation study for an updated version of its SimpleScreen CRC blood-based colorectal cancer screening test, meeting all primary and secondary endpoints. The study assessed the performance of assay and algorithm improvements, showing incre…